Quick Overview.
Melanotan I (MT-1) is a synthetic version of a hormone naturally produced in your body called alpha-melanocyte-stimulating hormone (α-MSH). Its primary job is to tell your skin cells (melanocytes) to produce melanin, the dark pigment that causes your skin to tan. It was originally developed by researchers at the University of Arizona in the 1980s as a way to give people a "sunless tan" to protect them from skin cancer. Today, a modified version of it is FDA-approved under the brand name Scenesse (Afamelanotide) to treat rare sunlight-sensitivity disorders.[1][2]
When you go out in the sun, the UV rays damage your skin. Your body responds by releasing a hormone that tells your skin to get darker (tan) to act as a natural sunscreen. Melanotan I is simply a lab-made version of that hormone. By injecting it, you trick your body into thinking it needs to produce a tan, even with very little actual sun exposure.[3]
- Primary Use Case: Safe, natural-looking skin tanning with minimal UV exposure.
- Mechanism: A highly selective agonist of the Melanocortin 1 Receptor (MC1R), which stimulates melanocytes to produce eumelanin (dark pigment).[4]
- Who it is for: People with fair skin (Type 1 or 2) who want to develop a protective base tan without burning, or anyone wanting a deep tan without excessive UV damage.
- Who it is NOT for: People with a history of melanoma or atypical moles.
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
confidence_tier: well-established
Melanotan I is generally considered much safer and milder than its famous cousin, Melanotan II. However, it will permanently darken existing freckles and moles. If you have a history of melanoma or atypical moles, you should not use this peptide, as it stimulates the exact cells (melanocytes) that turn into skin cancer.[5]
Standard Dosing
Note: Dosing is usually split into a "Loading Phase" to build the tan, and a "Maintenance Phase" to keep it.
| Phase | Dose | Frequency | Timing |
|---|---|---|---|
| Loading Phase | 1 mg (1000 mcg) | Once daily | Evening (to sleep through any nausea) |
| Maintenance Phase | 1 mg (1000 mcg) | 1 to 2 times per week | Anytime |
Reconstitution Math (Example for a 10mg vial)
- Add 2 mL of Bacteriostatic Water to the 10mg vial.
- 1 mg dose = 0.20 mL (20 units on an insulin syringe)
Injection Site Guide
- Where to Inject: Subcutaneous fat in the abdomen or thigh.
Cycle Length & Discontinuation Protocol
- Cycle Length: Can be used continuously during the summer months.
- Discontinuation: Once you stop injecting, the tan will slowly fade over 1 to 2 months as your skin naturally sheds and replaces itself.
Nutritional Support & Recommended Supplements.
confidence_tier: well-established
| Supplement | Rationale | Recommended Dose |
|---|---|---|
| Vitamin D3 | Because you will be spending less time in the sun to get a tan, you may need to supplement Vitamin D to maintain healthy levels. | 2000 - 5000 IU daily. |
| Antioxidants (Vitamin C/E) | To protect the skin from the oxidative stress of the UV exposure required to activate the tan. | Daily. |
Safety, Interactions & Side Effect Management.
confidence_tier: well-established
Side Effect Profile
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Nausea | Mild | Common | Inject right before bed so you sleep through it. Usually subsides after 3-4 days. |
| Facial Flushing | Mild | Common | A warm, red flush immediately after injection. Passes within 30 minutes. |
| Darkening of Moles/Freckles | Moderate | Universal | Existing freckles will get very dark before the rest of the skin catches up. |
Contraindications
- Absolute: Individuals with a personal or family history of Melanoma.
- Absolute: Individuals with numerous atypical or dysplastic nevi (moles).
- Absolute: Pregnant or breastfeeding women.
Drug Interactions
- Tanning Beds (Excessive UV): Moderate. MT-1 makes your skin hyper-responsive to UV light. Using a tanning bed for your normal duration while on MT-1 can result in an unnaturally dark, almost greyish tan.
Common Stacks & Combinations.
confidence_tier: community
| Stack | Goal | Rationale |
|---|---|---|
| Melanotan I + PT-141 | Tanning + Libido | Synergistic. PT-141 is a derivative of Melanotan II that only affects libido. Stacking MT-1 (for the tan) with PT-141 (for the libido) allows the user to control both effects separately, rather than taking MT-2 and getting both simultaneously. |
Body Composition & Training Guide.
confidence_tier: community
- The Freckle Effect: Users universally report that their freckles get incredibly dark before the rest of their skin catches up. This is normal but can look strange during the first two weeks.
- The Sunburn Protection: Fair-skinned (Type 1 and 2) users report that once the MT-1 tan sets in, they are virtually immune to sunburns, even during prolonged sun exposure.
Storage, Handling & Accessibility.
confidence_tier: well-established
- Storage (Lyophilized): Store in the freezer (-20°C) for up to 3-5 years, or in the fridge (2-8°C) for 1-2 years.
- Storage (Reconstituted): Must be stored in the fridge (2-8°C). Good for 14-21 days.
- WADA Status: Not explicitly banned, but falls under the "unapproved substances" category.
- Cost & Accessibility: Widely available from research chemical vendors, usually ~$30 - $50 per 10mg vial.
Bloodwork Monitoring Guide.
confidence_tier: well-established
There are no specific blood markers required for Melanotan I use.
- Dermatological Monitoring: The most important "monitoring" is visual. Have a dermatologist perform a full-body mole check before starting and once a year during use.
Comparison to Similar Compounds.
confidence_tier: well-established
| Feature | Melanotan I (MT-1) | Melanotan II (MT-2) | PT-141 (Bremelanotide) |
|---|---|---|---|
| Primary Effect | Tanning | Tanning + Libido + Fat Loss | Libido / Erectile Dysfunction |
| Receptor Affinity | MC1R (Skin) | MC1R, MC3R, MC4R (Skin + Brain) | MC3R, MC4R (Brain) |
| Nausea | Mild | Severe | Moderate |
| Spontaneous Erections | No | Yes | Yes |
Deep Dive (For Advanced Researchers).
confidence_tier: well-established
Mechanism of Action
Melanotan I (Afamelanotide) is a synthetic, linear, tridecapeptide analog of naturally occurring alpha-melanocyte-stimulating hormone (α-MSH). Its amino acid sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2.[6]
The key structural differences from native α-MSH are the substitution of norleucine (Nle) for methionine at position 4, and D-phenylalanine (D-Phe) for L-phenylalanine at position 7. These modifications make MT-1 highly resistant to enzymatic degradation, extending its half-life from minutes (native α-MSH) to roughly 1-2 hours.[7]
Cellular Pathways
- The Melanocortin Receptors: There are five known melanocortin receptors (MC1R through MC5R). MT-1 is a highly selective, full agonist of the MC1R receptor, which is located primarily on the surface of melanocytes in the skin and hair follicles.[4]
- Eumelanin Production: When MT-1 binds to MC1R, it activates adenylate cyclase, increasing intracellular cAMP. This triggers the transcription of microphthalmia-associated transcription factor (MITF), which upregulates the enzymes tyrosinase, TRP-1, and TRP-2.[8]
- The Shift: This enzymatic cascade forces the melanocyte to switch from producing pheomelanin (red/yellow pigment) to eumelanin (brown/black pigment). The eumelanin is then packaged into melanosomes and transported to the surrounding keratinocytes, creating a dark, photoprotective tan.[3]
Clinical Trial Summary
- Erythropoietic Protoporphyria (EPP): EPP is a rare genetic disorder where exposure to sunlight causes severe, agonizing pain in the skin. Clinuvel Pharmaceuticals developed MT-1 into a slow-release subcutaneous implant (Scenesse). In Phase III clinical trials, Scenesse significantly increased the amount of time EPP patients could spend in direct sunlight without pain. The FDA approved Scenesse in 2019.[2]
- The Implant vs. The Peptide: The FDA-approved implant releases the drug slowly over 2 months. The biohacker method of injecting the lyophilized peptide daily results in sharp peaks and troughs in blood serum levels, which is why the peptide causes more acute nausea than the implant.[9]
Synergy & Antagonism Analysis
- UV Synergy: MT-1 is not a true "sunless" tanner. While it upregulates the machinery to produce melanin, the actual production and distribution of melanin still require a mild UV trigger. Without any UV exposure, the tan will be very subtle. With mild UV exposure, the tan will be profound.[10]
Frequently Asked Questions (FAQ).
confidence_tier: community
Q: Why do people use MT-2 if MT-1 is safer? A: MT-2 is much cheaper to manufacture, requires far less UV light to get dark, and has the added "benefits" of appetite suppression and extreme libido enhancement. MT-1 is purely for tanning.
Q: Will it change my hair or eye color? A: It can temporarily darken your hair (especially beard hair in men) if used for long periods, as MC1R receptors are present in hair follicles. It will not change your eye color.
Q: Do I have to go in the sun? A: Yes, but very little. 10-15 minutes of natural sunlight a few times a week is enough to trigger the massive melanin production. You do not need to burn or lay out for hours.
Q: Why did my freckles get so dark? A: Freckles are concentrated clusters of melanocytes. Because they have more receptors, they respond to the peptide faster and stronger than the rest of your skin. Once the rest of your skin tans, the freckles will blend in.
International Regulatory Status.
confidence_tier: well-established
| Agency | Status | Notes |
|---|---|---|
| US FDA | Approved | Approved as an implant (Scenesse) for EPP. Unapproved as an injectable peptide. |
| WADA | Unapproved | Not explicitly banned, but falls under unapproved substances. |
| UK MHRA | Approved | Approved as Scenesse for EPP. |
| EU EMA | Approved | Approved as Scenesse for EPP. |
Decision Tree.
confidence_tier: community
[Goal: Dark Tan with Minimal Sun Exposure?]
|
+-- Do you have a history of melanoma or atypical moles?
|
+-- (Yes) -> STOP: Do not use Melanotan I.
|
+-- (No) -> Are you willing to inject daily during the loading phase?
|
+-- (No) -> Use standard sunless tanning lotions.
|
+-- (Yes) -> Inject 1mg daily before bed.
Get 10-15 mins of UV exposure 2-3x per week.Schema.org Data.
{
"@context": "https://schema.org",
"@type": "MedicalEntity",
"name": "Melanotan I",
"alternateName": ["Afamelanotide", "Scenesse", "MT-1"],
"description": "A synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as an MC1R agonist to stimulate melanin production and tanning.",
"legalStatus": {
"@type": "DrugLegalStatus",
"description": "FDA-approved as an implant (Scenesse) for EPP. Injectable peptide form is unapproved."
}
}What we cited.
- Hadley ME, et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol. 1998;11:575-595. doi:10.1007/0-306-47384-4_25
- Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48-59. doi:10.1056/NEJMoa1411481
- Dorr RT, et al. Increased Eumelanin Expression and Tanning Is Induced by a Superpotent Melanotropin (Nle4-D-Phe7-alpha-MSH) in Humans. Clin Cancer Res. 2000;6(10):3804-3810.
- Minder EI, et al. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clin Pharmacokinet. 2017;56(8):815-823. doi:10.1007/s40262-016-0501-5
- Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. doi:10.1111/ijd.13631
- Ugwu SO, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18(3):259-269.
- Wensink D, et al. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatol. 2020;156(5):570-575. doi:10.1001/jamadermatol.2020.0352
- Evans-Brown M, et al. Use of melanotan I and II in the general population. BMJ. 2009;338:b566. doi:10.1136/bmj.b566
- Iii DJC, et al. A glimpse into the underground market of melanotan. J Am Acad Dermatol. 2018;79(3):588-589. doi:10.1016/j.jaad.2018.02.049
- Brennan R, et al. An unhealthy glow? A review of melanotan use and associated clinical outcomes. Performance Enhancement & Health. 2015;3(2):78-92. doi:10.1016/j.peh.2015.01.001